{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:36:02Z","timestamp":1788478562270,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004687","name":"Universidad de Murcia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004687","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring (TDM) in inflammatory rheumatic diseases (RMDs) is gaining interest. However, there are unresolved questions about the best practices for implementing TDM effectively in clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The primary objective of this study was to evaluate whether early TDM of adalimumab predicts drug survival at 52 weeks in patients with RMDs. The secondary objective was to identify factors associated with pharmacokinetic failure and treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study included patients aged\u2009\u2265\u200918 years with RMDs who initiated adalimumab therapy. Early TDM was performed within the first 26 weeks, and adalimumab trough levels (ATL) and anti-drug antibodies were measured. Drug survival was assessed at 52 weeks and defined as the time from adalimumab initiation to discontinuation for any reason. Multivariate analyses were conducted to identify factors influencing outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 194 patients, of whom 56.7% exhibited ATL below the therapeutic range during the first 26 weeks. In the multivariate analysis, subtherapeutic concentrations were significantly associated with higher weight (OR\u2009=\u20091.02;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.040) and ankylosing spondylitis diagnosis (OR\u2009=\u20093.68;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). At 52 weeks, 43.8% of patients had discontinued adalimumab. Low ATL (&lt;\u20091 \u00b5g\/mL) was strongly associated with treatment discontinuation (OR\u2009=\u20097.31;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), while concomitant methotrexate reduced this risk (OR\u2009=\u20090.46;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Early TDM of adalimumab predicts drug persistence and underscores its clinical relevance as a proactive tool to guide personalized treatment and reduce the risk of treatment failure. These findings highlight the importance of incorporating TDM into routine practice to optimize therapeutic outcomes.\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                \u2022\n                                <jats:italic>Early TDM of adalimumab in rheumatic diseases shows that low drug exposure predicts reduced drug survival at 52 weeks.<\/jats:italic>\n                                \u2022\n                                <jats:italic>Approximately half of the patients exhibit low adalimumab exposure with the standard dose (40 mg every other week).<\/jats:italic>\n                                \u2022\n                                <jats:italic>Body weight and methotrexate use significantly impact adalimumab levels.<\/jats:italic>\n                                \u2022\n                                <jats:italic>Immunogenicity, found in 14.4% of patients with low ADL levels, underscores the need for early ADA detection to prevent non-response and discontinuation.<\/jats:italic>\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-025-07307-0","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T09:10:37Z","timestamp":1737191437000},"page":"1009-1018","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: \u201cearly therapeutic drug monitoring of adalimumab\u201d"],"prefix":"10.1007","volume":"44","author":[{"given":"Patricia","family":"Ortiz-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-7250","authenticated-orcid":false,"given":"Carles","family":"Iniesta-Naval\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Urbieta-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Gasc\u00f3n-C\u00e1novas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"7307_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48:35\u201345 (Erratum in: Arthritis Rheum. 2003;48:855)","journal-title":"Arthritis Rheum."},{"key":"7307_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, Pangan AL (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial ABILITY-1. Ann Rheum Dis 72:815\u2013822","journal-title":"Ann Rheum Dis"},{"key":"7307_CR3","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, Adalimumab effectiveness in psoriatic arthritis trial study group (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:3279\u201389","journal-title":"Arthritis Rheum"},{"key":"7307_CR4","doi-asserted-by":"publisher","first-page":"764518","DOI":"10.1155\/2013\/764518","volume":"2013","author":"A Arora","year":"2013","unstructured":"Arora A, Mahajan A, Spurden D, Boyd H, Porter D (2013) Long-term drug survival of TNF inhibitor therapy in RA patients: a systematic review of European National Drug Registers. Int J Rheumatol 2013:764518","journal-title":"Int J Rheumatol"},{"key":"7307_CR5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40259-022-00559-1","volume":"36","author":"JE Gehin","year":"2022","unstructured":"Gehin JE, Goll GL, Brun MK, Jani M, Bolstad N, Syversen SW (2022) Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine. BioDrugs 36:731\u2013748","journal-title":"BioDrugs"},{"key":"7307_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/17425255.2017.1353602","volume":"13","author":"N Van Herwaarden","year":"2017","unstructured":"Van Herwaarden N, Van Den Bemt BJF, Wientjes MHM, Kramers C, Den Broeder AA (2017) Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. Expert Opin Drug Metab Toxicol 13:843\u2013857","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"7307_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1136\/annrheumdis-2020-216996","volume":"79","author":"E Ulijn","year":"2020","unstructured":"Ulijn E, den Broeder N, Wientjes M, van Herwaarden N, Meek I, Tweehuysen L, van der Maas A, van den Bemt BJ, den Broeder AA (2020) Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD. Ann Rheum Dis 79:867\u2013873","journal-title":"Ann Rheum Dis"},{"key":"7307_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","volume":"74","author":"MF Pouw","year":"2015","unstructured":"Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, Wolbink G (2015) Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 74:513\u2013518","journal-title":"Ann Rheum Dis"},{"key":"7307_CR9","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921\u2013926","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"7307_CR10","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1136\/annrheumdis-2015-207530","volume":"74","author":"R Sanmarti","year":"2015","unstructured":"Sanmarti R, Inciarte-Mundo J, Estrada-Alarcon P, Garcia-Manrique M, Narvaez J, Rodriguez-Moreno J, Gomez-Centeno A, Pascal M, Yag\u00fce J (2015) Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study. Ann Rheum Dis 74(8):e42","journal-title":"Ann Rheum Dis"},{"key":"7307_CR11","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/rheumatology\/kead525","volume":"63","author":"I Jyssum","year":"2024","unstructured":"Jyssum I, Gehin JE, Sexton J, Kristianslund EK, Hu Y, Warren DJ, Kvien TK, Haavardsholm EA, Syversen SW, Bolstad N, Goll GL (2024) Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases. Rheumatology (Oxford) 63:1746\u20131755","journal-title":"Rheumatology (Oxford)"},{"key":"7307_CR12","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/art.39169","volume":"67","author":"M Jani","year":"2015","unstructured":"Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A, Biologics in rheumatoid arthritis genetics and genomics study syndicate collaborators (2015) Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol. 67:2011\u20139 (Erratum in: Arthritis Rheumatol. 2015;67:3096)","journal-title":"Arthritis Rheumatol."},{"key":"7307_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/1744666X.2019.1630273","volume":"15","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS (2019) Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol 15:837\u2013848","journal-title":"Expert Rev Clin Immunol"},{"key":"7307_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/FTD.0000000000000410","volume":"39","author":"G Paintaud","year":"2017","unstructured":"Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan-Angoulvant T, Pascual-Salcedo D, Mulleman D (2017) Rationale for therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Ther Drug Monit 39:339\u2013343","journal-title":"Ther Drug Monit"},{"key":"7307_CR15","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/bcp.13192","volume":"83","author":"C Bastida","year":"2017","unstructured":"Bastida C, Ru\u00edz V, Pascal M, Yag\u00fce J, Sanmart\u00ed R, Soy D (2017) Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis? Br J Clin Pharmacol 83:962\u2013975","journal-title":"Br J Clin Pharmacol"},{"key":"7307_CR16","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","volume":"17","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA (2019) Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 17:1655\u20131668","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7307_CR17","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.14309\/ajg.0000000000001396","volume":"116","author":"AS Cheifetz","year":"2021","unstructured":"Cheifetz AS, Abreu MT, Afif W, Cross RK, Dubinsky MC, Loftus EV Jr, Osterman MT, Saroufim A, Siegel CA, Yarur AJ, Melmed GY, Papamichael K (2021) A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. Am J Gastroenterol 116:2014\u20132025","journal-title":"Am J Gastroenterol"},{"key":"7307_CR18","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/ecco-jcc\/jjz162","volume":"14","author":"MP Sparrow","year":"2020","unstructured":"Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X (2020) Therapeutic drug monitoring of biologics during induction to prevent primary non-response. J Crohns Colitis 14:542\u2013556","journal-title":"J Crohns Colitis"},{"key":"7307_CR19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.gastrohep.2024.01.007","volume":"47","author":"F Rodr\u00edguez-Moranta","year":"2024","unstructured":"Rodr\u00edguez-Moranta F, Arg\u00fcelles-Arias F, Hinojosa Del Val J, Iborra Colomino M, Mart\u00edn-Arranz MD, Mench\u00e9n Viso L, Mu\u00f1oz N\u00fa\u00f1ez F, Ricart G\u00f3mez E, S\u00e1nchez-Hern\u00e1ndez JG, Vald\u00e9s-Delgado T, Guardiola Cap\u00f3n J, Barreiro-de Acosta M, Ma\u00f1osa Ciria M, Zabana Abdo Y, Guti\u00e9rrez Casbas A (2024) Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn\u2019s Disease and Ulcerative Colitis. Gastroenterol Hepatol. 47:522\u201352","journal-title":"Gastroenterol Hepatol."},{"key":"7307_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","volume":"82","author":"CL Krieckaert","year":"2023","unstructured":"Krieckaert CL, van Tubergen A, Gehin JE, Hern\u00e1ndez-Breijo B, Le M\u00e9l\u00e9do G, Balsa A, B\u00f6hm P, Cucnik S, Elkayam O, Goll GL, Hooijberg F, Jani M, Kiely PD, McCarthy N, Mulleman D, Navarro-Comp\u00e1n V, Payne K, Perry ME, Plasencia-Rodriguez C, Stones SR, Syversen SW, de Vries A, Ward KM, Wolbink G, Isaacs JD (2023) EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 82:65\u201373","journal-title":"Ann Rheum Dis"},{"key":"7307_CR21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/FTD.0000000000000421","volume":"39","author":"F Medina","year":"2017","unstructured":"Medina F, Plasencia C, Goupille P, Ternant D, Balsa A, Mulleman D (2017) Current practice for therapeutic drug monitoring of biopharmaceuticals in rheumatoid arthritis. Ther Drug Monit 39:364\u2013369","journal-title":"Ther Drug Monit"},{"key":"7307_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/FTD.0000000000000400","volume":"39","author":"F Medina","year":"2017","unstructured":"Medina F, Plasencia C, Goupille P, Paintaud G, Balsa A, Mulleman D (2017) Current practice for therapeutic drug monitoring of biopharmaceuticals in spondyloarthritis. Ther Drug Monit 39:360\u2013363","journal-title":"Ther Drug Monit"},{"key":"7307_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/cts.12738","volume":"13","author":"X Ding","year":"2020","unstructured":"Ding X, Zhu R, Wu J, Xue L, Gu M, Miao L (2020) Early adalimumab and anti-adalimumab antibody levels for prediction of primary nonresponse in ankylosing spondylitis patients. Clin Transl Sci 13:547\u2013554","journal-title":"Clin Transl Sci"},{"key":"7307_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bcp.12509","volume":"79","author":"D Ternant","year":"2015","unstructured":"Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerr\u00e9 T, Le Lo\u00ebt X, Vittecoq O, Goupille P, Mulleman D, Paintaud G (2015) Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol 79:286\u2013297","journal-title":"Br J Clin Pharmacol"},{"key":"7307_CR25","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nri1937","volume":"6","author":"H Tilg","year":"2006","unstructured":"Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772\u2013783","journal-title":"Nat Rev Immunol"},{"key":"7307_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10067-018-4355-0","volume":"38","author":"A Mart\u00ednez-Feito","year":"2019","unstructured":"Mart\u00ednez-Feito A, Plasencia-Rodr\u00edguez C, Navarro-Comp\u00e1n V, Hern\u00e1ndez-Breijo B, Gonz\u00e1lez M\u00c1, Monjo I, Nu\u00f1o L, Nozal P, Pascual-Salcedo D, Balsa A (2019) The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Clin Rheumatol 38:949\u2013954","journal-title":"Clin Rheumatol"},{"key":"7307_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L (2017) Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs 31:299\u2013316","journal-title":"BioDrugs"},{"key":"7307_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/joim.13495","volume":"292","author":"MK Brun","year":"2022","unstructured":"Brun MK, Goll GL, J\u00f8rgensen KK, Sexton J, Gehin JE, Sandanger \u00d8, Olsen IC, Klaasen RA, Warren DJ, M\u00f8rk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA, Syversen SW (2022) Risk factors for anti-drug antibody formation to infliximab: secondary analyses of a randomised controlled trial. J Intern Med 292:477\u2013491","journal-title":"J Intern Med"},{"key":"7307_CR29","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2018-213403","volume":"77","author":"S Bitoun","year":"2018","unstructured":"Bitoun S, Nocturne G, Ly B, Krzysiek R, Roques P, Pruvost A, Paoletti A, Pascaud J, D\u00f6nnes P, Florence K, Gleizes A, Hincelin-Mery A, Allez M, Hacein-Bey-Abina S, Mackay F, Pallardy M, Le Grand R, Mariette X (2018) Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. Ann Rheum Dis 77:1463\u20131470","journal-title":"Ann Rheum Dis"},{"key":"7307_CR30","doi-asserted-by":"publisher","first-page":"11632","DOI":"10.1038\/s41598-021-91177-4","volume":"11","author":"B Hern\u00e1ndez-Breijo","year":"2021","unstructured":"Hern\u00e1ndez-Breijo B, Navarro-Comp\u00e1n V, Plasencia-Rodr\u00edguez C, Parodis I, Gehin JE, Mart\u00ednez-Feito A, Novella-Navarro M, Mezcua A, Warren DJ, Nozal P, Pascual-Salcedo D, Balsa A (2021) BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors. Sci Rep 11:11632","journal-title":"Sci Rep"},{"key":"7307_CR31","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40744-021-00345-5","volume":"8","author":"C G\u00f3mez-Arango","year":"2021","unstructured":"G\u00f3mez-Arango C, Gorostiza I, \u00dacar E, Garc\u00eda-Vivar ML, P\u00e9rez CE, De Dios JR, Alvarez B, Ruibal-Escribano A, Stoye C, Vasques M, Belzunegui J, Escobar A, Trancho Z, Ruiz Del Agua A, Del Rio L, Jorquera C, Diez E, Mart\u00ednez A, Nagore D (2021) Cost-effectiveness of therapeutic drug monitoring-guided adalimumab therapy in rheumatic diseases: a prospective, pragmatic trial. Rheumatol Ther 8:1323\u20131339","journal-title":"Rheumatol Ther"},{"key":"7307_CR32","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2017-211781","volume":"77","author":"MJ I\u2019Ami","year":"2018","unstructured":"I\u2019Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ (2018) Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis 77:484\u201348","journal-title":"Ann Rheum Dis"},{"key":"7307_CR33","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1001\/jama.2021.4172","volume":"325","author":"SW Syversen","year":"2021","unstructured":"Syversen SW, Goll GL, J\u00f8rgensen KK, Sandanger \u00d8, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljos\u00e5 MKA, Haugen AJ, Nj\u00e5lla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune T, Ystr\u00f8m CM, Torp R, Mielnik P, M\u00f8rk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA (2021) Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial. JAMA 325:1744\u20131754","journal-title":"JAMA"},{"key":"7307_CR34","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1001\/jama.2021.21316","volume":"326","author":"SW Syversen","year":"2021","unstructured":"Syversen SW, J\u00f8rgensen KK, Goll GL, Brun MK, Sandanger \u00d8, Bj\u00f8rlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljos\u00e5 MKA, Haugen AJ, Nj\u00e5lla RJ, Zettel C, Ystr\u00f8m CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM, Strand EK, Mielnik P, Torp R, M\u00f8rk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA (2021) Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA 326:2375\u20132384","journal-title":"JAMA"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07307-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T10:23:05Z","timestamp":1748600585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07307-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["7307"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07307-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}